MET and Miyoshi myopathy: Due to our earlier observation23, 24 that epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) inhibitors reduce the activation of the MAPK and PI3K/AKT signalling pathways, and thus significantly decrease the viability and invasion of CM, we decided to test whether these drugs would also be effective in MM.